MovDisordV3, Main, Exploration, bibRecordById, pubmed:8990067

Risperidone‐induced tardive dyskinesia and parkinsonism

Identifieur interne : 005268 ( Main/Exploration ); précédent : 005267; suivant : 005269

Risperidone‐induced tardive dyskinesia and parkinsonism

Auteurs : Katrina A. Gwinn [États-Unis] ; John N. Caviness [États-Unis]

Source :

Movement Disorders [ 0885-3185 ] ; 1997-01.

RBID : ISTEX:56447F59BF02D72B157F5B808190BC6E6C8A6B3D

Descripteurs français

Pascal (Inist)
- Antagoniste, Antipsychotique, Cavité buccale, Dyskinésie, Etude cas, Homme, Langue, Mâle, Parkinsonisme, Psychotrope, Rispéridone, Récepteur dopaminergique, Récepteur sérotoninergique, Toxicité, Trouble bipolaire.
Wicri :
- topic : Homme.

English descriptors

KwdEn :
- Aged, Antagonist, Antipsychotic, Antipsychotic Agents (adverse effects), Antipsychotic Agents (therapeutic use), Bipolar Disorder (drug therapy), Bipolar disorder, Case study, Dopamine receptor, Dyskinesia, Dyskinesia, Drug-Induced (etiology), Human, Humans, Male, Neurologic Examination (drug effects), Oral cavity, Parkinson Disease, Secondary (chemically induced), Parkinsonism, Psychotropic, Risperidone, Risperidone (adverse effects), Risperidone (therapeutic use), Serotoninergic receptor, Tongue, Toxicity.
MESH :
- chemical , adverse effects : Antipsychotic Agents, Risperidone.
- chemical , therapeutic use : Antipsychotic Agents, Risperidone.
- chemically induced : Parkinson Disease, Secondary.
- drug effects : Neurologic Examination.
- drug therapy : Bipolar Disorder.
- etiology : Dyskinesia, Drug-Induced.
- Aged, Humans, Male.

Url:

https://api.istex.fr/document/56447F59BF02D72B157F5B808190BC6E6C8A6B3D/fulltext/pdf

DOI: 10.1002/mds.870120123

Affiliations:

Le document en format XML

<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">Risperidone‐induced tardive dyskinesia and parkinsonism</title>
<author><name sortKey="Gwinn, Katrina A" sort="Gwinn, Katrina A" uniqKey="Gwinn K" first="Katrina A" last="Gwinn">Katrina A. Gwinn</name>
</author>
<author><name sortKey="Caviness, John N" sort="Caviness, John N" uniqKey="Caviness J" first="John N." last="Caviness">John N. Caviness</name>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">ISTEX</idno>
<idno type="RBID">ISTEX:56447F59BF02D72B157F5B808190BC6E6C8A6B3D</idno>
<date when="1997" year="1997">1997</date>
<idno type="doi">10.1002/mds.870120123</idno>
<idno type="url">https://api.istex.fr/document/56447F59BF02D72B157F5B808190BC6E6C8A6B3D/fulltext/pdf</idno>
<idno type="wicri:Area/Istex/Corpus">003919</idno>
<idno type="wicri:Area/Istex/Curation">003919</idno>
<idno type="wicri:Area/Istex/Checkpoint">003891</idno>
<idno type="wicri:doubleKey">0885-3185:1997:Gwinn K:risperidone:induced:tardive</idno>
<idno type="wicri:source">PubMed</idno>
<idno type="RBID">pubmed:8990067</idno>
<idno type="wicri:Area/PubMed/Corpus">004719</idno>
<idno type="wicri:Area/PubMed/Curation">004719</idno>
<idno type="wicri:Area/PubMed/Checkpoint">004583</idno>
<idno type="wicri:Area/Ncbi/Merge">004C64</idno>
<idno type="wicri:Area/Ncbi/Curation">004C64</idno>
<idno type="wicri:Area/Ncbi/Checkpoint">004C64</idno>
<idno type="wicri:doubleKey">0885-3185:1997:Gwinn K:risperidone:induced:tardive</idno>
<idno type="wicri:Area/Main/Merge">008296</idno>
<idno type="wicri:source">INIST</idno>
<idno type="RBID">Pascal:97-0142934</idno>
<idno type="wicri:Area/PascalFrancis/Corpus">003288</idno>
<idno type="wicri:Area/PascalFrancis/Curation">003536</idno>
<idno type="wicri:Area/PascalFrancis/Checkpoint">003160</idno>
<idno type="wicri:doubleKey">0885-3185:1997:Gwinn K:risperidone:induced:tardive</idno>
<idno type="wicri:Area/Main/Merge">008515</idno>
<idno type="wicri:Area/Main/Curation">005268</idno>
<idno type="wicri:Area/Main/Exploration">005268</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title level="a" type="main" xml:lang="en">Risperidone‐induced tardive dyskinesia and parkinsonism</title>
<author><name sortKey="Gwinn, Katrina A" sort="Gwinn, Katrina A" uniqKey="Gwinn K" first="Katrina A" last="Gwinn">Katrina A. Gwinn</name>
<affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Department of Neurology Mayo Clinic Scottsdale Scottsdale, Arizona</wicri:regionArea>
<placeName><region type="state">Arizona</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Caviness, John N" sort="Caviness, John N" uniqKey="Caviness J" first="John N." last="Caviness">John N. Caviness</name>
<affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Department of Neurology Mayo Clinic Scottsdale Scottsdale, Arizona</wicri:regionArea>
<placeName><region type="state">Arizona</region>
</placeName>
</affiliation>
</author>
</analytic>
<monogr></monogr>
<series><title level="j">Movement Disorders</title>
<title level="j" type="sub">Official Journal of the Movement Disorder Society</title>
<title level="j" type="abbrev">Mov. Disord.</title>
<idno type="ISSN">0885-3185</idno>
<idno type="eISSN">1531-8257</idno>
<imprint><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher>
<pubPlace>Hoboken</pubPlace>
<date type="published" when="1997-01">1997-01</date>
<biblScope unit="vol">12</biblScope>
<biblScope unit="issue">1</biblScope>
<biblScope unit="page" from="119">119</biblScope>
<biblScope unit="page" to="121">121</biblScope>
</imprint>
<idno type="ISSN">0885-3185</idno>
</series>
<idno type="istex">56447F59BF02D72B157F5B808190BC6E6C8A6B3D</idno>
<idno type="DOI">10.1002/mds.870120123</idno>
<idno type="ArticleID">MDS870120123</idno>
</biblStruct>
</sourceDesc>
<seriesStmt><idno type="ISSN">0885-3185</idno>
</seriesStmt>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Aged</term>
<term>Antagonist</term>
<term>Antipsychotic</term>
<term>Antipsychotic Agents (adverse effects)</term>
<term>Antipsychotic Agents (therapeutic use)</term>
<term>Bipolar Disorder (drug therapy)</term>
<term>Bipolar disorder</term>
<term>Case study</term>
<term>Dopamine receptor</term>
<term>Dyskinesia</term>
<term>Dyskinesia, Drug-Induced (etiology)</term>
<term>Human</term>
<term>Humans</term>
<term>Male</term>
<term>Neurologic Examination (drug effects)</term>
<term>Oral cavity</term>
<term>Parkinson Disease, Secondary (chemically induced)</term>
<term>Parkinsonism</term>
<term>Psychotropic</term>
<term>Risperidone</term>
<term>Risperidone (adverse effects)</term>
<term>Risperidone (therapeutic use)</term>
<term>Serotoninergic receptor</term>
<term>Tongue</term>
<term>Toxicity</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="adverse effects" xml:lang="en"><term>Antipsychotic Agents</term>
<term>Risperidone</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Antipsychotic Agents</term>
<term>Risperidone</term>
</keywords>
<keywords scheme="MESH" qualifier="chemically induced" xml:lang="en"><term>Parkinson Disease, Secondary</term>
</keywords>
<keywords scheme="MESH" qualifier="drug effects" xml:lang="en"><term>Neurologic Examination</term>
</keywords>
<keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Bipolar Disorder</term>
</keywords>
<keywords scheme="MESH" qualifier="etiology" xml:lang="en"><term>Dyskinesia, Drug-Induced</term>
</keywords>
<keywords scheme="MESH" xml:lang="en"><term>Aged</term>
<term>Humans</term>
<term>Male</term>
</keywords>
<keywords scheme="Pascal" xml:lang="fr"><term>Antagoniste</term>
<term>Antipsychotique</term>
<term>Cavité buccale</term>
<term>Dyskinésie</term>
<term>Etude cas</term>
<term>Homme</term>
<term>Langue</term>
<term>Mâle</term>
<term>Parkinsonisme</term>
<term>Psychotrope</term>
<term>Rispéridone</term>
<term>Récepteur dopaminergique</term>
<term>Récepteur sérotoninergique</term>
<term>Toxicité</term>
<term>Trouble bipolaire</term>
</keywords>
<keywords scheme="Wicri" type="topic" xml:lang="fr"><term>Homme</term>
</keywords>
</textClass>
<langUsage><language ident="en">en</language>
</langUsage>
</profileDesc>
</teiHeader>
</TEI>
<affiliations><list><country><li>États-Unis</li>
</country>
<region><li>Arizona</li>
</region>
</list>
<tree><country name="États-Unis"><region name="Arizona"><name sortKey="Gwinn, Katrina A" sort="Gwinn, Katrina A" uniqKey="Gwinn K" first="Katrina A" last="Gwinn">Katrina A. Gwinn</name>
</region>
<name sortKey="Caviness, John N" sort="Caviness, John N" uniqKey="Caviness J" first="John N." last="Caviness">John N. Caviness</name>
</country>
</tree>
</affiliations>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Wicri/Santé/explor/MovDisordV3/Data/Main/Exploration

HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 005268 | SxmlIndent | more

HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 005268 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Wicri/Santé
   |area=    MovDisordV3
   |flux=    Main
   |étape=   Exploration
   |type=    RBID
   |clé=     ISTEX:56447F59BF02D72B157F5B808190BC6E6C8A6B3D
   |texte=   Risperidone‐induced tardive dyskinesia and parkinsonism
}}

This area was generated with Dilib version V0.6.23.
Data generation: Sun Jul 3 12:29:32 2016. Site generation: Wed Feb 14 10:52:30 2024

Movement Disorders (revue)

Risperidone‐induced tardive dyskinesia and parkinsonism

Risperidone‐induced tardive dyskinesia and parkinsonism

Source :

Descripteurs français

English descriptors

Links toward previous steps (curation, corpus...)

Le document en format XML

Pour manipuler ce document sous Unix (Dilib)

Pour mettre un lien sur cette page dans le réseau Wicri

	Movement Disorders (revue)
	Attention, ce site est en cours de développement ! Attention, site généré par des moyens informatiques à partir de corpus bruts. Les informations ne sont donc pas validées.